meta
|
evidence
oncology
Living systematic review and meta-analysis
castration-resistant prostate cancer (CRPC)
metastatic (mCRPC) - 1st line (L1)
3
metastatic (mCRPC) - 2nd line (L2)
immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
ipilimumab alone
anti-PD-(L)1
pembrolizumab based treatment